NASDAQ:ARGS - Argos Therapeutics Stock Price, News, Headlines & Rumors Sign in or create an account to add this stock to your watchlist. Get Started $0.2701 +0.14 (+107.61 %) (As of 08/15/2018 03:13 PM ET)Previous Close$0.1284Today's RangeN/A52-Week Range$0.10 - $5.80VolumeN/AAverage Volume496,858 shsMarket Capitalization$2.29 millionP/E RatioN/ADividend YieldN/ABeta1.53 Company ProfileAnalyst RatingsChartEarnings HistoryFinancialsInsider TradesHeadlinesOptions ChainSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Argos Therapeutics, Inc., an immuno-oncology company, focuses on the development and commercialization of individualized immunotherapies for the treatment of cancer and infectious diseases in North America. The company develops immunotherapies based on its proprietary technology platform, Arcelis. Its product candidates include rocapuldencel-T, which is in Phase III clinical trial for the treatment of metastatic renal cell carcinoma; and in Phase II clinical trial to treat early stage renal cell carcinoma and muscle invasive bladder cancer. The company also develops AGS-004, which is in Phase II clinical trials for the treatment of human immunodeficiency virus. The company was formerly known as Merix Bioscience, Inc. and changed its name to Argos Therapeutics, Inc. in October 2004. Argos Therapeutics, Inc. was founded in 1997 and is based in Durham, North Carolina. Receive ARGS News and Ratings via Email Sign-up to receive the latest news and ratings for ARGS and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical SymbolNASDAQ:ARGS CUSIPN/A Webwww.argostherapeutics.com Phone919-287-6300 Debt Debt-to-Equity Ratio-1.31 Current Ratio1.80 Quick Ratio1.80 Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$1.90 million Price / Sales1.51 Cash FlowN/A Price / CashN/A Book Value($1.63) per share Price / Book-0.17 Profitability EPS (Most Recent Fiscal Year)N/A Net Income$-40,570,000.00 Net Margins-2,135.68% Return on EquityN/A Return on Assets-171.85% Miscellaneous Employees39 Outstanding Shares10,590,000Market Cap$2.29 million Argos Therapeutics (NASDAQ:ARGS) Frequently Asked Questions What is Argos Therapeutics' stock symbol? Argos Therapeutics trades on the NASDAQ under the ticker symbol "ARGS." When did Argos Therapeutics' stock split? How did Argos Therapeutics' stock split work? Argos Therapeutics's stock reverse split on Friday, January 19th 2018. The 1-20 reverse split was announced on Thursday, January 18th 2018. The number of shares owned by shareholders was adjusted after the market closes on Thursday, January 18th 2018. An investor that had 100 shares of Argos Therapeutics stock prior to the reverse split would have 5 shares after the split. How were Argos Therapeutics' earnings last quarter? Argos Therapeutics Inc. (NASDAQ:ARGS) posted its quarterly earnings results on Wednesday, August, 9th. The biopharmaceutical company reported ($4.20) earnings per share (EPS) for the quarter, topping the Zacks' consensus estimate of ($4.50) by $0.30. The biopharmaceutical company earned $0.07 million during the quarter, compared to analyst estimates of $0.10 million. View Argos Therapeutics' Earnings History. When is Argos Therapeutics' next earnings date? Argos Therapeutics is scheduled to release their next quarterly earnings announcement on Wednesday, August, 15th 2018. View Earnings Estimates for Argos Therapeutics. Who are some of Argos Therapeutics' key competitors? Some companies that are related to Argos Therapeutics include Concordia International (CXRXF), Tonix Pharmaceuticals (TNXP), Agile Therapeutics (AGRX), OHR Pharmaceutical (OHRP), Uluru (ULUR), Peak Pharmaceuticals (PKPH), MYOS Co. common stock (MYOS), Pain Therapeutics (PTIE), ContraVir Pharmaceuticals (CTRV), Immune Therapeutics (IMUN), Cellectar Biosciences (CLRB), RXi Pharmaceuticals (RXII), Marina Biotech (MRNA), Apricus Biosciences (APRI) and Boston Therapeutics (BTHE). Who are Argos Therapeutics' key executives? Argos Therapeutics' management team includes the folowing people: Mr. Jeffrey D. Abbey, Pres, CEO & Director (Age 56)Dr. Charles A. Nicolette Ph.D., Chief Scientific Officer and VP of R&D (Age 56)Dr. Richard D. Katz, VP & CFO (Age 54)Ms. Lori R. Harrelson CPA, VP of Fin. & Principal Accounting Officer (Age 49)Mr. John D. Menditto, VP of Corp. Communications and Investor Relations Has Argos Therapeutics been receiving favorable news coverage? Headlines about ARGS stock have trended somewhat positive recently, Accern Sentiment reports. The research group ranks the sentiment of news coverage by analyzing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Argos Therapeutics earned a media and rumor sentiment score of 0.18 on Accern's scale. They also assigned news stories about the biopharmaceutical company an impact score of 48.86 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near term. View Recent Headlines for Argos Therapeutics. How do I buy shares of Argos Therapeutics? Shares of ARGS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is Argos Therapeutics' stock price today? One share of ARGS stock can currently be purchased for approximately $0.2701. How big of a company is Argos Therapeutics? Argos Therapeutics has a market capitalization of $2.29 million and generates $1.90 million in revenue each year. Argos Therapeutics employs 39 workers across the globe. How can I contact Argos Therapeutics? Argos Therapeutics' mailing address is 4233 TECHNOLOGY DR, DURHAM NC, 27704. The biopharmaceutical company can be reached via phone at 919-287-6300. MarketBeat Community Rating for Argos Therapeutics (NASDAQ ARGS)Community Ranking: 3.1 out of 5 ( )Outperform Votes: 255 (Vote Outperform)Underperform Votes: 158 (Vote Underperform)Total Votes: 413MarketBeat's community ratings are surveys of what our community members think about Argos Therapeutics and other stocks. Vote "Outperform" if you believe ARGS will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ARGS will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 8/15/2018 by MarketBeat.com StaffFeatured Article: How are Outstanding Shares Different from Authorized Shares?